Table 2_Hong Kong Urological Association–Hong Kong Society of Uro-Oncology 2025 consensus

The Hong Kong Urological Association–Hong Kong Society of Uro-Oncology 2025 consensus document contains 42 accepted statements on managing locally advanced or metastatic renal cell carcinoma. It was developed via a Delphi process with a panel of 14 experts and an extensive literature review. The document was last updated in April 2026 and is shared under a CC-BY-4.0 license.

Use Cases

• Analyzing clinical consensus trends based on the 42 accepted statements.
• Studying the Delphi method application in medical guideline development based on the described panel process.
• Comparing treatment recommendations for different RCC subtypes (e.g., clear cell, sarcomatoid) based on the described consensus areas.
• Reviewing the evolution of adjuvant and immunotherapy recommendations based on the comparison to a previous version mentioned.

Strengths

• Contains 42 specific, voted consensus statements providing structured clinical guidance.
• Developed via a formal Delphi process involving 14 expert clinicians (6 urologists, 8 oncologists).
• Statements were accepted only with ≥80% agreement, indicating strong panel alignment.

Limitations

• The dataset is a 672.8 KB DOCX document; its textual format requires manual extraction for structured analysis.
• Column-level documentation is absent; field semantics must be inferred after download.
• The consensus reflects expert opinion from a specific region (Hong Kong/Asia-Pacific), which may limit generalizability.

Provenance

Source

Hong Kong Urological Association and Hong Kong Society of Uro-Oncology

Collection Method

Delphi meetings, extensive literature review, and anonymous panel voting.

Time Range

2025 consensus (published/updated 2026).

Freshness

Last updated 2026-04-23 04:19:11

Geography

Hong Kong, with intended relevance for the Asia-Pacific region.